Nektar Therapeutics, a biopharmaceutical company, develops various drug products and product candidates using its proprietary drug delivery technologies. Its technology platforms comprise PEGylation Technology designed to enhance the performance of various drug classes, including macromolecules, small molecules, and other drugs; and Pulmonary Technology, which includes technologies for drug formulation, powder processing, powder filling, and packaging, as well as dry powder inhaler devices and liquid nebulizer devices. The company's technologies are used in 10 approved products; 3 partner programs that have been filed for with the FDA; and 12 development programs in human clinical trials. Its partnered products include Tobramycin inhalation powder, a Phase III clinical product for treating lung infections; NKTR-061, a Phase II clinical product for gram-negative pneumonias; Ciprofloxacin Inhalation Powder, a Phase II clinical product for lung infections; Pulmonary dronabinol, a Phase II product for migraine; and Exubera Inhalation Powder for adult type 1 and type 2 diabetes. The company's partnered product portfolio also comprises Neulasta for neutropenia; PEGASY for Hepatitis-C; Somavert for Acromegaly; PEG-INTRON for Hepatitis-C; Macugen for age-related macular degeneration; CIMZIA for Crohn's disease; MIRCERA for renal anemia and chronic kidney disease; CIMZIA for rheumatoid arthritis; Hematide, a Phase III product for Anemia; Macugen, a Phase II clinical trial product for diabetic macular edema and retinal vein occlusion; and CDP 791, a Phase II product for nonsmall cell lung cancer. In addition, Nektar's proprietary products include NKTR-102, a Phase II trial product for colorectal cancer; and NKTR-118, which is in Phase II clinical trials for opioid-induced constipation and other manifestations of opioid bowel dysfunction. The company was founded in 1990 and is headquartered in San Carlos, California.